Schedule 13G ownership disclosure
CRISPR Therapeutics AG
Security class unavailable · CUSIP: H17182108
Event date: 2019-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 2,690,470
- Percent of class
- 4.4000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001341004-20-000055
- Form type
- SC 13G
- Filer
- CRISPR Therapeutics AG
- CIK
- CIK 1674416
- Filed
- Feb 13, 2020
- Reporting period
- Dec 31, 2019
- Description
- Schedule 13G beneficial ownership